211 related articles for article (PubMed ID: 8166672)
21. Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism.
Arai H; Escobedo JA
Mol Pharmacol; 1996 Sep; 50(3):522-8. PubMed ID: 8794890
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
23. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
24. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP.
Geyer M; Schweins T; Herrmann C; Prisner T; Wittinghofer A; Kalbitzer HR
Biochemistry; 1996 Aug; 35(32):10308-20. PubMed ID: 8756686
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms regulating Raf-1 activity in signal transduction pathways.
Morrison DK
Mol Reprod Dev; 1995 Dec; 42(4):507-14. PubMed ID: 8607983
[TBL] [Abstract][Full Text] [Related]
26. Different structural organization of Ras and Rho effector domains.
Self AJ; Paterson HF; Hall A
Oncogene; 1993 Mar; 8(3):655-61. PubMed ID: 8437849
[TBL] [Abstract][Full Text] [Related]
27. CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation.
Jabado N; Pallier A; Le Deist F; Bernard F; Fischer A; Hivroz C
J Immunol; 1997 Jan; 158(1):94-103. PubMed ID: 8977179
[TBL] [Abstract][Full Text] [Related]
28. Proteins regulating Ras and its relatives.
Boguski MS; McCormick F
Nature; 1993 Dec; 366(6456):643-54. PubMed ID: 8259209
[TBL] [Abstract][Full Text] [Related]
29. Signal transduction: untangling its golden promise.
Edgington SM
Biotechnology (N Y); 1992 Feb; 10(2):152, 154. PubMed ID: 1368226
[No Abstract] [Full Text] [Related]
30. Interactions between p21ras proteins and their GTPase activating proteins.
Polakis P; McCormick F
Cancer Surv; 1992; 12():25-42. PubMed ID: 1386285
[TBL] [Abstract][Full Text] [Related]
31. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis.
Balmain A; Brown K; Bremner R
Immunol Ser; 1990; 51():75-88. PubMed ID: 2128916
[No Abstract] [Full Text] [Related]
32. [Oncogenes and tumor suppressor genes in the signal transduction pathways of growth factors].
Buday L
Orv Hetil; 1994 Nov; 135(47):2579-84. PubMed ID: 7824256
[TBL] [Abstract][Full Text] [Related]
33. Molecular approaches towards an anti-ras drug.
Sigal IS; Smith GM; Jurnak F; Marsico-Ahern JD; D'Alonzo JS; Scolnick EM; Gibbs JB
Anticancer Drug Des; 1987 Oct; 2(2):107-15. PubMed ID: 3130069
[TBL] [Abstract][Full Text] [Related]
34. Cooperative translational control of gene expression by Ras and Akt in cancer.
Parsa AT; Holland EC
Trends Mol Med; 2004 Dec; 10(12):607-13. PubMed ID: 15567331
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of p21ras upon T-cell activation.
Downward J; Graves JD; Warne PH; Rayter S; Cantrell DA
Nature; 1990 Aug; 346(6286):719-23. PubMed ID: 2201921
[TBL] [Abstract][Full Text] [Related]
36. Regulatory mechanisms for ras proteins.
Downward J
Bioessays; 1992 Mar; 14(3):177-84. PubMed ID: 1586371
[TBL] [Abstract][Full Text] [Related]
37. [Farnesyl transferase inhibitors (anti-Ras). A new class of anticancer agents].
Levy R
Presse Med; 1995 Apr 15-22; 24(15):725-9. PubMed ID: 7784406
[TBL] [Abstract][Full Text] [Related]
38. Raf-1 interferes with Ras and Rap1A effector functions in yeast.
Ruggieri R; Macdonald SG; Callow M; McCormick F
Mol Biol Cell; 1994 Feb; 5(2):173-81. PubMed ID: 8019003
[TBL] [Abstract][Full Text] [Related]
39. Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction.
Stone JC; Colleton M; Bottorff D
Mol Cell Biol; 1993 Dec; 13(12):7311-20. PubMed ID: 8246952
[TBL] [Abstract][Full Text] [Related]
40. Reversion of a human tumour cell line containing oncogenic p21ras is associated with a defect in the post-translational processing of the ras protein.
Tilbrook PA; Paterson HF; Marshall CJ
Oncogene; 1995 Feb; 10(4):805-9. PubMed ID: 7862461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
